Posts by Mourabit Halima

October 21-27, 2024, Wuhan, at the 9th Academic Symposium of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (IHPBA), we interviewed Professor René Adam, the current President of the IHPBA and a famous surgeon at AP-HP Paul Brousse Hospital in Paris, France, to share his research explorations on the use of liver transplantation combined with chemotherapy for the treatment of colorectal cancer with liver metastases (CRLM).

The "Expert Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer (2024 Edition)" was recently released under the guidance of Academician Jinming Yu from Shandong Cancer Hospital, Professor Ying Cheng from Jilin Cancer Hospital, and Professor Liang’an Chen from the Chinese PLA General Hospital. This consensus provides evidence and guidance for the application of radiotherapy combined with immunotherapy in clinical practice. In an exclusive interview with Oncology Frontier, Dr. Zhiyong Ma from Henan Cancer Hospital discussed the optimal duration of immunotherapy as consolidation therapy, individualized treatment in radiotherapy combined with immunotherapy, and future research directions.

For advanced non-small cell lung cancer (NSCLC), treatment strategies typically include platinum-based doublet chemotherapy, immunotherapy, and targeted therapy, with specific methods determined by molecular biomarker testing. Current unmet medical needs for advanced NSCLC patients include a lack of new treatment options following the failure of immunotherapy combinations, resistance to targeted therapies, and strategies to improve efficacy.

The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology and the Beijing Health Management Development Foundation, took place in Xiamen from September 25-29, 2024. During the conference, several lung cancer-focused forums highlighted cutting-edge research and progress in the field both domestically and internationally. During the event, Oncology Frontier had the opportunity to interview Dr. Tony Mok from the Faculty of Medicine at The Chinese University of Hong Kong. He shared his insights on the current role and future outlook of biomarker testing in clinical practice for lung cancer.

With breast cancer incidence rates on the rise globally, it has become a major health threat to women. In China, the challenge of breast cancer control is equally significant, and improving the quality of diagnosis, treatment, and survival rates for breast cancer patients has become a critical task in healthcare. International cooperation has been a driving force in advancing breast cancer clinical research worldwide. At the 2024 Breast Cancer Standardized Diagnosis, Treatment, and Quality Control Conference, Academician Binghe Xu from the Cancer Hospital Chinese Academy of Medical Sciences delivered a report on the current state and future of breast cancer clinical research in China. Oncology Frontier had the privilege of interviewing Academician Xu, who shared insights on how Chinese scholars, by participating in international multicenter clinical trials, have not only gained experience in advanced research methods and management but also earned a prominent role on the global stage, contributing significantly to new treatment options for breast cancer patients worldwide.